Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for immuno-inflammatory diseases. The company operates within the biotechnology and pharmaceutical research industries and primarily generates value through the advancement of internally developed drug candidates rather than commercial product sales. Its core strategy centers on targeting novel molecular pathways implicated in inflammatory and immune-mediated conditions.
Originally founded in 2012, Aclaris initially operated as a dermatology-focused biopharmaceutical company with both clinical development and commercial dermatology assets. In 2021, the company completed a strategic transformation by divesting its commercial dermatology business to Bausch Health Companies Inc., subsequently repositioning itself as a pure-play immuno-inflammatory drug development company. This evolution shifted Aclaris toward earlier-stage innovation with an emphasis on proprietary small-molecule therapeutics.
Business Operations
Aclaris conducts its operations primarily through a single reportable segment focused on immuno-inflammatory therapeutics development. The company’s activities include drug discovery, preclinical research, and clinical development, with revenue historically derived from collaboration agreements, asset divestitures, and milestone payments rather than product sales. As of the most recent public disclosures, Aclaris does not maintain a commercial sales infrastructure.
The company’s technology platform emphasizes small-molecule kinase inhibition, particularly pathways involved in inflammatory signaling. Aclaris retains full or partial rights to its development-stage assets and has engaged in strategic collaborations with large pharmaceutical partners to advance certain programs. Its operations are conducted internally and through a network of third-party contract research organizations, with no manufacturing facilities of its own disclosed in public filings.
Strategic Position & Investments
Aclaris’ strategic direction is centered on advancing its lead immuno-inflammatory pipeline assets while managing capital efficiently following the exit from commercial dermatology. A key focus has been ATI-450, an oral MK2 pathway inhibitor investigated for multiple inflammatory indications. The program was the subject of a global collaboration and license agreement with Eli Lilly and Company, though subsequent amendments and program status disclosures indicate changes to the scope of that collaboration; specific current rights and development responsibility are inconclusive based on available public sources.
The company has historically pursued selective acquisitions and internal investments to strengthen its discovery capabilities rather than building a broad portfolio of late-stage assets. Following its strategic reset, Aclaris has emphasized early-stage innovation, portfolio prioritization, and balance sheet preservation, with no major acquisitions publicly disclosed after the divestiture of its dermatology business.
Geographic Footprint
Aclaris Therapeutics is headquartered in the United States, with its principal executive offices located in Pennsylvania. The company’s operational footprint is primarily domestic, reflecting its status as a development-stage biotechnology firm without international commercial operations.
Despite its limited physical presence outside the U.S., Aclaris maintains a global strategic reach through international clinical trials and partnerships with multinational pharmaceutical companies. Its pipeline assets are intended for global markets, subject to successful development and regulatory approvals, but direct international operations remain limited based on public disclosures.
Leadership & Governance
Aclaris is led by an executive team with experience in biotechnology development, corporate strategy, and capital markets. The leadership emphasizes scientific innovation, disciplined capital allocation, and strategic partnering as core elements of the company’s operating philosophy.
Key executives include:
- Neal C. Walker – President and Chief Executive Officer
- Brent Sheppard – Chief Financial Officer
- Mary L. Smith – Chief Legal and Administrative Officer
- Robert A. Kornstein, M.D. – Chief Medical Officer
The company is governed by a board of directors comprising executives and independent directors with backgrounds in pharmaceuticals, finance, and healthcare. Governance practices and leadership roles are disclosed in SEC filings, including annual reports and proxy statements, with no material governance disputes publicly reported.